New indication joins a series of single-agent and combination treatments for various cancers.
The FDA has approved ramucirumab (CYRAMZA, Elli Lilly and Company) as a single agent for hepatocellular carcinoma (HCC) in patients who have an alpha fetoprotein (AFP) greater than 400 g/mL and have bene treated with sorafenib.
Approval is based upon a multinational, randomized, double-blind, placebo-controlled, multicenter study involving 292 patients with advanced HCC with AFP that either showed disease progression on or after treatment with sorafenib, or were intolerant to sorafenib.
The most common adverse reactions observed throughout the trial included fatigue, peripheral edema, hypertension, abdominal pain, decreased appetite, proteinuria, nausea, and ascites. Most common laboratory abnormalities included hypoalbuminemia, hyponatremia, and thrombocytopenia.
For HCC, the recommended dose is 8 mg/kg every 2 weeks.
Continuous Glucose Monitoring Could Improve Outcomes in Pediatric Patients With Leukemia/Lymphoma
July 2nd 2024A pilot study presented at the American Diabetes Association 84th Scientific Sessions showed that CGM technology could produce reliable results without complications in children with leukemia/lymphoma at risk for hyperglycemia.